All In Biotech

Drug Trial Radar · NCT00721825

Study of NeuroAid In Enhancing Recovery After Stroke

A Double-Blinded, Placebo-Controlled, Randomized Phase II Pilot Study to Investigate the Potential Efficacy of a Traditional Chinese Medicine NeuroAid In Enhancing Recovery After Stroke (TIERS)

Last checked: Nov 19, 2026Latest source record: Jul 24, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Jan 2008

Primary completion

Jul 2008

Study completion Jul 2008

Sponsor

Lead sponsor
Moleac Pte Ltd.Industry
Sponsor type
Industry
First posted
Jul 24, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 21 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

TIERS is a phase II to generate detailed preliminary data on the efficacy of NeuroAid in post-stroke recovery, and to assess the utility of the rehabilitation outcome measure instruments used.

Conditions

  • Stroke
  • Cerebral Infarction

Interventions

  • NeuroaidDrug

    Neuroaid capsules, 4 capsules, three times per day, during one month

  • Neuroaid matched PlaceboDrug

    Neuroaid matched placebo 4 capsules three times per day during one month

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Fugl-Meyer assessmentTime frame: 4 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tan Tock Seng Rehabilitation department

    Singapore, Singapore

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.